von Willebrand Disease Profile Interpretation
Use
This test is used for the interpretation of testing performed as part of a profile for detecting deficiency or abnormality of von Willebrand factor (VWF) and related deficiency of factor VIII coagulant activity. It also aids in subtyping von Willebrand disease (VWD) as type 1, type 2 variants, or type 3. The test is not useful for detecting hemophilia carriers or differentiating between specific types of VWD, such as type 2A versus 2B or platelet-type VWD.
Special Instructions
Not provided.
Limitations
This test should be performed prior to and in the absence of recent transfusion or von Willebrand factor replacement therapy. Borderline low levels of VWF antigen or activity may be observed in normal individuals, especially those with blood group O. Repeat testing or clinical correlation may be required to differentiate between acquired and hereditary forms of VWD. This test is not useful for differentiating certain types of VWD without additional testing like ristocetin-induced platelet aggregation testing.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 48595-3 - von Willebrand eval PPP-Imp
- 18771-6 - Provider signing name
- 48595-3 - von Willebrand eval PPP-Imp
Result Turnaround Time
7-12 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
Not provided
Container
Na Cit
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |